Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Neoplasma (Bratislava)

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4149/NEO_2014_031PMID 24471939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of Pleurodesis

  2012cited by this paper
• Molecular changes in mesothelioma with an impact on prognosis and treatment.

  2012cited by this paper
• Detection of carbonic anhydrase IX protein in the diagnosis of malignant pleural effusion by enzyme‐linked immunosorbent assay and immunocytochemistry

  2012cited by this paper
• Diagnostic value of metabolic phenotypes in malignant pleural effusions

  2011cited by this paper
• Chemotherapy and targeted therapies for unresectable malignant mesothelioma.

  2011cited by this paper
• Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung

  2011influential reference
• Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain.

  2010cited by this paper
• Second-line treatment for malignant pleural mesothelioma.

  2010cited by this paper
• Significance of pH regulation and carbonic anhydrases in tumour progression and implications for diagnostic and therapeutic approaches

  2008cited by this paper
• MN/CA9: a potential gene marker for detection of malignant cells in effusions

  2007influential reference
• Carbonic anhydrases as drug targets--an overview.

  2007cited by this paper
• Multidisciplinary treatment of malignant pleural mesothelioma.

  2007cited by this paper
• Malignant pleural mesothelioma: a comprehensive review.

  2006cited by this paper
• Tumor-associated carbonic anhydrases and their clinical significance.

  2006cited by this paper
• Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM).

  2006cited by this paper
• Advances in malignant mesothelioma.

  2005cited by this paper
• Role of Carbonic Anhydrase IX in Human Tumor Cell Growth, Survival, and Invasion

  2004cited by this paper
• Carbonic Anhydrase IX in Early-Stage Non–Small Cell Lung Cancer

  2004cited by this paper
• Review Article

  2004cited by this paper
• Hypoxia Inducible Carbonic Anhydrase IX, Marker of Tumour: Hypoxia, Survival Pathway and Therapy Target

  2004cited by this paper
• Pathology and genetics of tumours of the lung , pleura, thymus and heart

  2004cited by this paper
• Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study

  2003cited by this paper
• Hypoxia — a key regulatory factor in tumour growth

  2002cited by this paper
• Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.

  2001influential reference
• Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.

  2001cited by this paper
• Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

  2000influential reference
• Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines.

  1994cited by this paper
• Expression of MaTu‐MN protein in human tumor cultures and in clinical specimens

  1993cited by this paper
• A novel quasi-viral agent, MaTu, is a two-component system.

  1992cited by this paper
• Bmc Developmental Biology Expression of Transmembrane Carbonic Anhydrases, Caix and Caxii, in Human Development

  year unknowncited by this paper

• Nonmesothelial Spindle Cell Tumors of Pleura and Pericardium.

  2024cites this paper
• Correlation of Preclinical In Vivo Imaging Modalities and Immunohistochemistry for Tumor Hypoxia and Vasculature

  2024cites this paper
• Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.

  2024cites this paper
• New Immunohistochemical Markers for Pleural Mesothelioma Subtyping

  2023cites this paper
• Differential carbonic anhydrase activities control EBV-induced B-cell transformation and lytic cycle reactivation

  2023cites this paper
• Clear cell mesotheliomas with inactivating VHL mutations and near‐haploid genomic features

  2022cites this paper
• Factors, associated with elevated concentration of soluble carbonic anhydrase IX in plasma of women with cervical dysplasia

  2022cites this paper
• Immunochemistry in the work‐up of mesothelioma and its differential diagnosis and mimickers

  2021cites this paper
• Inhibitors of CA IX Enzyme Based on Polyhedral Boron Compounds

  2021cites this paper
• Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity

  2021cites this paper
• Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds

  2020cites this paper
• Mesothelioma Driver Genes, Ferroptosis, and Therapy

  2019cites this paper
• Biophysical, Biochemical, and Cell Based Approaches Used to Decipher the Role of Carbonic Anhydrases in Cancer and to Evaluate the Potency of Targeted Inhibitors

  2018cites this paper
• DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response

  2018cites this paper
• Different expression patterns of carbonic anhydrase IX in oral lichen planus and leukoplakia.

  2018cites this paper
• Carbonic Anhydrases: Role in pH Control and Cancer

  2018cites this paper
• Expression and therapeutic significance of estrogen receptor β in malignant pleural mesothelioma

  2017cites this paper
• Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.

  2016cites this paper
• KDM6B histone demethylase is an epigenetic regulator of estrogen receptor β expression in human pleural mesothelioma.

  2016cites this paper
• Switching off malignant mesothelioma: exploiting the hypoxic microenvironment

  2016influential citation
• Molecular genetic features of peritoneal mesothelioma

  2014cites this paper